Pargluva, a diabetes drug in development, has today been praised in the news for its effects on blood sugar levels. However, it is unlikely that Pargluva will ever make it onto the market following FDA approval delay and corporate concern.
The developer of the drug, Bristol -Myers Squibb, has announced that they will drop the drug from their pipeline . The reasons cited come after the drug had been linked to an elevated risk of heart attacks and strokes .
In order to clarify the effects of the drug on the human cardiovascular system, to gain regulatory approval, would be a long and expensive process. This would likely take five years, too long for the drug to reach its potential in the marketplace .
Pargluva was being developed in a partnership between Bristol-Myers Squibb and Merck. Merck dropped out of the development partnership in December 2005, following delays in approval by federal regulators.
Pargluva, which came in pill form, was intended to be a new form of non-insulin treatment to control blood sugar in type 2 diabetics . A financial analyst reportedly played down the effects on the share value, sales figures and ratings of the company .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…